                               SEQUENCE LISTING

<110> BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
 
<120> COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING PROSTATE
      CANCER

<130> 167688.011401/PCT

<140> PCT/US2019/013295
<141> 2019-01-11

<150> 62/616,134
<151> 2018-01-11

<160> 27    

<170> PatentIn version 3.5

<210> 1
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 1
gcaaccaguc ggugcguga                                                    19


<210> 2
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 2
ccgacuucug gugcuuuga                                                    19


<210> 3
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 3
gugaagaucu ugaccaaug                                                    19


<210> 4
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 4
gaucagcaua cacaaauua                                                    19


<210> 5
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 5
ggcgcuaugu guauuauua                                                    19


<210> 6
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 6
guauagagcg ugcagauaa                                                    19


<210> 7
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 7
ccgcaucuau gguuucuac                                                    19


<210> 8
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 8
caucuauggu uucuacgau                                                    19


<210> 9
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 9
cugguuacac cuuugggca                                                    19


<210> 10
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 10
uaaccaagcu gcaaucaug                                                    19


<210> 11
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 11
ggaauauuua uggaagaca                                                    19


<210> 12
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 12
gauaguaaga aaugcuaaa                                                    19


<210> 13
<211> 19
<212> RNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 13
uaaggcuaug aagagauac                                                    19


<210> 14
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 14
gtgtacgcct tctccatcaa a                                                 21


<210> 15
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic
      oligonucleotide

<400> 15
cacccgcaag accaacaaca t                                                 21


<210> 16
<211> 13
<212> PRT
<213> Homo sapiens

<400> 16
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 17
<211> 10
<212> PRT
<213> Homo sapiens

<400> 17
Pro Gly Gly Arg Pro Ile Thr Pro Pro Arg 
1               5                   10  


<210> 18
<211> 13
<212> PRT
<213> Mus musculus

<400> 18
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 19
<211> 10
<212> PRT
<213> Mus musculus

<400> 19
Pro Gly Gly Arg Pro Ile Thr Pro Pro Arg 
1               5                   10  


<210> 20
<211> 13
<212> PRT
<213> Rattus norvegicus

<400> 20
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 21
<211> 10
<212> PRT
<213> Rattus norvegicus

<400> 21
Pro Gly Gly Arg Pro Ile Thr Pro Pro Arg 
1               5                   10  


<210> 22
<211> 13
<212> PRT
<213> Xenopus laevis

<400> 22
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 23
<211> 10
<212> PRT
<213> Xenopus laevis

<400> 23
Asn Gln Ser Arg Pro Val Thr Pro Pro Arg 
1               5                   10  


<210> 24
<211> 13
<212> PRT
<213> Danio rerio

<400> 24
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 25
<211> 10
<212> PRT
<213> Danio rerio

<400> 25
Gly Ser Gly Arg Pro Val Thr Pro Pro Arg 
1               5                   10  


<210> 26
<211> 13
<212> PRT
<213> Drosophila melanogaster

<400> 26
Gly Glu Asn Asp Arg Gly Val Ser Phe Thr Phe Gly Ala 
1               5                   10              


<210> 27
<211> 10
<212> PRT
<213> Drosophila melanogaster

<400> 27
Ser Ser Gly Arg Pro Leu Thr Pro Pro Arg 
1               5                   10  


